---
title: "MONARCH 2"
slug: "monarch"
date: "2023-12-06"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[Hormone-receptor positive (HER2 negative)-of-metastatic breast cancer]]

# MONARCH 2

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2
A Randomized Clinical Trial

## Key Points

- Question
  - Does treatment with abemaciclib plus fulvestrant prolong the overall survival (OS) of patients with hormone receptor (HR)-positive, ERBB2 (formerly HER2)-negative advanced breast cancer who progressed during prior endocrine therapy?
- Findings
  - In the randomized, placebo-controlled MONARCH 2 trial of 669 patients with HR-positive, ERBB2-negative advanced breast cancer, abemaciclib plus fulvestrant significantly improved median OS to 46.7 months compared with 37.3 months for patients receiving placebo plus fulvestrant.
- Meaning
  - The addition of abemaciclib to fulvestrant provided a clinically meaningful median OS benefit of 9.4 months for patients with HR-positive, ERBB2-negative advanced breast cancer that had progressed on endocrine therapy.
  -

## TLDR

åœ¨ä¸€é …åç‚ºMONARCH 2çš„Phase 3ç ”ç©¶ç™¼ç¾ï¼šé‡å°å·²ç¶“ç¶“æ­·å…§åˆ†æ³Œæ²»ç™‚çš„è·çˆ¾è’™å—é«”é™½æ€§ã€ERBB2é™°æ€§æ™šæœŸä¹³è…ºç™Œæ‚£è€…ï¼Œä½¿ç”¨abemaciclibåŠ fulvestrantç›¸è¼ƒæ–¼åƒ…ä½¿ç”¨fulvestrantï¼Œæ–¼ä¸­æœŸåˆ†ææ™‚å·²é”æˆé å…ˆè¨­å®šçš„ä¸»è¦çµå±€-èª¿æŸ¥è€…è©•ä¼°ä¹‹ âœ– ç„¡é€²å±•ç”Ÿå­˜æœŸï¼Œä¸”åœ¨é‡è¦æ¬¡è¦çµå±€-æ•´é«”ç”Ÿå­˜æœŸæ–¹é¢æœ‰é¡¯è‘—æå‡ (46.7å€‹æœˆ vs 37.3å€‹æœˆï¼›é¢¨éšªæ¯”0.757ï¼›På€¼ç‚º0.01)

- æ­¤å¤–ï¼Œä½¿ç”¨abemaciclibçš„å‰¯ä½œç”¨å®‰å…¨æ€§è‰¯å¥½ï¼Œä¸”ä½¿ç”¨è©²è—¥ç‰©å¯å»¶é²æ‚£è€…æ¥å—ä¸‹ä¸€ç·šåŒ–ç™‚çš„æ™‚é–“
- è©²ç ”ç©¶å·²åœ¨ClinicalTrials.govè¨»å†Š (NCT02107703) ã€‚
